<DOC>
	<DOCNO>NCT01530659</DOCNO>
	<brief_summary>This clinical trial single-site , 30 patient study participant early stage retinitis pigmentosa , Usher syndrome ( type 2 3 ) . Funding Source - FDA OOPD Foundation Fighting Blindness .</brief_summary>
	<brief_title>Retinal Imaging Subjects Implanted With Ciliary Neurotrophic Factor ( CNTF ) -Releasing Encapsulated Cell Implant Early-stage Retinitis Pigmentosa</brief_title>
	<detailed_description>This clinical trial prospective , randomize , double-masked , sham-controlled trial 30 study participant early-stage retinitis pigmentosa , Usher syndrome ( type 2 3 ) . The trial conduct University California , San Francisco . Individuals diseases experience gradually worsen vision ultimately may lead blindness due genetic condition specialize cell eye 's retina call photoreceptor cell cease function and/or die . The study intend use relatively new , non-invasive technology call AOSLO ( adaptive optic scan laser ophthalmoscopy ) combination routine standard care measurement call sdOCT ( Spectral Domain Optical Coherence Tomography ) demonstrate device secrete investigational drug call CNTF ( Ciliary Neurotrophic Factor ) surgically place patient 's eye , one type photoreceptor call `` cone photoreceptors '' preserve gradual loss vision halt .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<mesh_term>Usher Syndromes</mesh_term>
	<criteria>1 . Participant must 18 55 year age . 2 . Participant must diagnosis retinitis pigmentosa Usher Syndrome type 2 3 ( without profound deafness cochlear implant ) . 3 . Participant must understand sign protocol inform consent . If participant 's vision impair point he/she read informed consent document , document read participant entirety . 4 . Bestcorrected visual acuity must worse 20/63 ( least 59 letter ) . 5 . Participants must clear natural lens . 6 . Participants must less 6 diopter myopia . 7 . Participants must medically able undergo ophthalmic surgery NT501 device insertion able undergo assessment test associate protocol . 8 . Females childbearing potential ( woman last menses &lt; 1 year prior screen ) must agree use effective form birth control study onset complete study . 9 . Participants must reproducible baseline AOSLO image . 10 . Participants must interocular symmetry disease severity . 11 . Participant 's clinical diagnosis must consistent retinal degeneration set retinitis pigmentosa ( RP ) dystrophy . 1 . Participant medically unable comply study procedure followup visit . 2 . Participant follow lens opacity : cortical opacity &gt; standard 3 , posterior subcapsular opacity &gt; standard 3 , nuclear opacity &gt; standard 3 ; participant pseudophakic aphakic . 3 . Participant history corneal opacification lack optical clarity . 4 . Participant undergone LASIK surgery refractive surgery either eye . 5 . Participant nystagmus . 6 . Participant great 6 diopter myopia . 7 . Participant cystoid macular edema cyst present within 4 degree foveal center prevent acquisition least 7 region interest clear image cone photoreceptors . 8 . Participant few 7 region interest ( ROIs ) present baseline AOSLO image montage . 9 . Participant retinal vascular disease diabetic retinopathy prior retinal vascular occlusive disease . 10 . Participant chronic requirement ( e.g. , ≥4 week time ) ocular medication disease ( ) judgment examine physician vision threatening , toxic lens , retina , optic nerve may affect primary outcome . 11 . Participant requirement acyclovir and/or relate product study duration . To eligible study , participant must discontinue use product prior enrollment must continue product complete study . 12 . Participant receive systemic steroid immunosuppressive medication . 13 . Participant currently participate participate clinical trial drug ocular systemic administration within last 6 month . 14 . Participant previous exposure intraocular device implant eye ( exclude intraocular lens ) . 15 . Participant uveitis retinal inflammatory disease . 16 . Participant history myocardial infarction within last 12 month . 17 . Participant pregnant lactating . 18 . Participant consider immunodeficient known history HIV . 19 . Participant history ocular herpes zoster . 20 . Participant chemotherapy . 21 . Participant history malignancy , except study participant cancer treat successfully ≥5 year prior inclusion trial . 22 . Participant severe hear disability ear . 23 . Participant diagnose treat amblyopia infant . 24 . Participant , opinion study doctor , good study subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Retinitis pigmentosa</keyword>
	<keyword>Usher syndrome type 2</keyword>
	<keyword>Usher syndrome type 3</keyword>
	<keyword>Cone photoreceptor</keyword>
	<keyword>Vision</keyword>
	<keyword>Blind</keyword>
</DOC>